July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Short-Term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP CSC) – A Randomized, Placebo-Controlled Study
Author Affiliations & Notes
  • Roger A Goldberg
    Bay Area Retina Associates, Walnut Creek, California, United States
  • Jeffrey S. Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Roger Goldberg, Allergan (C), Corcept (F), Emmetrope (I), Roche/Genentech (C), Roche/Genentech (F), Santen (F); Jeffrey Heier, Corcept (F), Corcept (C)
  • Footnotes
    Support  Corcept Therapeutics
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 782. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Roger A Goldberg, Jeffrey S. Heier; Short-Term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP CSC) – A Randomized, Placebo-Controlled Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):782.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the efficacy and safety of mifepristone, a GR2-receptor antagonist, for patients with chronic and/or recurrent central serous chorioretinopathy.

Methods : Randomized, double-masked, multi-site, placebo-controlled trial of mifepristone 300- and 900-mg daily for four weeks. Central retinal thickness (CRT) and visual acuity (BCVA) were measured throughout the study.

Results : 30 patients were randomized to placebo, 300- or 900 mg. Patients assigned to active treatment had a significant reduction in CRT (82 microns; p<0.05) and improvement in BCVA (3.6 ETDRS letters; p<0.05). Patients assigned to placebo did not have a significant change in CRT (47 microns) or BCVA (0.7 letters). Comparison of change in CRT between active- and placebo-treated patients did not reach statistical significance (p=0.15). Mifepristone was well tolerated.

Conclusions : Oral mifepristone may reduce subretinal fluid and improve visual acuity in patients with CSC. Larger studies are warranted to extend these findings.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×